Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS: NWBO · Delayed Price · USD
0.477
+0.017 (3.67%)
Apr 25, 2024, 3:59 PM EDT - Market closed
Company Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.
The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Ms. Linda F. Powers J.D. |
Contact Details
Address: 4800 Montgomery Lane, Suite 800 Bethesda, Maryland 20814 United States | |
| Phone | (240) 497-9024 |
| Website | nwbio.com |
Stock Details
| Ticker Symbol | NWBO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001072379 |
| CUSIP Number | 66737P600 |
| ISIN Number | US66737P6007 |
| Employer ID | 94-3306718 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Linda F. Powers J.D. | Chairperson, Chief Executive Officer, President, Chief Financial Officer and Chief Accounting Officer |
| Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary and Director |
| Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer |
| Leslie J. Goldman | Senior Vice President and General Counsel |
| Jean M. Davis | Chief Information Officer |
| David Innes | Vice President of Investor Relations |
| Pankaj R. Shah C.A., CPA | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Nov 16, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Aug 9, 2023 | 10-Q | Quarterly Report |
| May 10, 2023 | 10-Q | Quarterly Report |
| Mar 8, 2023 | 8-K | Current Report |
| Feb 28, 2023 | 10-K | Annual Report |